Success Story
Ori Biotech’s mission is to eliminate barriers to patient access of cell and gene therapies (CGTs) through the use of innovation and by rethinking how those therapies are manufactured.
| Region/Nation | UK wide |
|---|---|
| Sector | Life Sciences |
| Programme | Core Programme |
| Fund Managers |
The company is developing a platform for the bespoke and flexible manufacture of CGTs and is deploying both automation and standardisation in manufacturing to help the pharma industry bring their products to market at true commercial scale. The company has partnered with Hitachi Chemical and G-con for development of its hardware platform, as well as Achilles Therapeutics for testing of the platform for manufacturing of a novel cell therapy.
Ori Biotech’s platform will help increase throughput, improve quality and decrease costs in order to enable widespread patient access to life-saving cell and gene therapies. At present, these types of therapies are prohibitively expensive for both payers and healthcare systems.
Investment from Amadeus Capital and Kindred Capital in January 2020 enabled Ori Biotech to move product development further and faster than the company could have done on its own. The company has since raised a $30 million in an October 2020 Series A round, followed by a further $100 million in a Series B round in January 2022.
Tags related to this content:
Quick links
More success stories
Read a success story about Xampla
Xampla has developed an entirely new generation of materials, made from plants, that replaces plastics.
Read a success story about Quantexa
Quantexa is a data and analytics specialist which has developed a software platform for organisations to help them make meaningful, evidence-based decision using data and machine learning.
Read a success story about Thought Machine
Thought Machine is providing the next generation of core banking platforms using software it has built natively for cloud infrastructure to help banks move away from a reliance on outdated IT infrastructure.